Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Hepatic encephalopathy is caused by the effects on the brain of substances that under normal
circumstances are efficiently metabolized in the liver. The hyperammonemia is the main factor
responsible for the development of hepatic encephalopathy. In patients with cirrhosis, the
reduction in hepatocellular function and generation of portosystemic shunts contribute to
increase serum ammonium. The current therapeutic approaches, are aimed at reducing blood
ammonium levels.
Administration of the non-absorbable disaccharides, have become standard treatment of hepatic
encephalopathy.There are no adequate clinical trials comparing the efficacy of
L-Ornithine-L-Aspartate (LOLA) infusion against lactose enemas in the treatment of acute
hepatic encephalopathy.
Phase:
Phase 4
Details
Lead Sponsor:
Centro Regional para el Estudio de las Enfermedades Digestivas